• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip Launches 'Small Stocks, Big Money' Podcast

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email

    New podcast series shines a spotlight on undervalued small-cap and microcap stocks

    ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."

    Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing listeners with an insider perspective they won't find anywhere else.

    "Small Stocks, Big Money is not just a podcast. It's a mission to empower everyday investors by providing them with the knowledge and insights they need to discover potentially lucrative investment opportunities," said Gentry. "We're taking our 30 plus years of experience in the microcap space and sharing it with the world. Our vision is to shed light on these lesser-known companies that hold the potential to deliver substantial returns."

    Episodes of "Small Stocks, Big Money" are now available for streaming on major platforms including Spotify, Amazon, and Apple.

    The debut episodes of "Small Stocks, Big Money" feature Sharps Technology (NASDAQ:STSS), BullFrog AI (NASDAQ:BFRG), Zomedica (NYSE:ZOM), Lantern Pharma (NASDAQ:LTRN), and Reviva Pharmaceuticals (NASDAQ:RVPH).

    Listeners are encouraged to subscribe to the series to stay up-to-date with the latest episodes. Each installment promises to be a deep dive into the fast-paced world of microcap investing, offering unique insights that could shape the future of your investment portfolio.

    The "Small Stocks, Big Money" podcast series takes inspiration from the book of the same name written by Gentry. Published by Wiley, the book offers a unique perspective on microcap investing through a series of insightful interviews with small stock superstars. It provides readers with key lessons learned from successful investments and helps them understand how to discover promising companies, develop solid investment strategies, and navigate the risks associated with smaller companies. This wealth of knowledge now extends to the podcast, making it an invaluable resource for anyone interested in the world of small stocks and big money.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    info@redchip.com

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/771825/RedChip-Launches-Small-Stocks-Big-Money-Podcast

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG
    $LTRN
    $RVPH
    $STSS

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    Lantern Pharma Inc.
    $LTRN
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    Lantern Pharma Inc.
    $LTRN
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

    Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300. Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate. Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with amivantamab plus

    6/2/26 8:13:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

    GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced it has appointed commercial technology sales and scientific-focused leaders to support the momentum of the Company's commercial business driven growth strategy. The new commercial management team brings combined expertise in scaling enterprise technology, implementing go-to-market strategic initiatives across global markets, driving and scaling revenue, and advancing target identification, discovery, and c

    6/2/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer

    Mission-critical appointment with extensive public company, multinational, and emerging growth experience as SkyAI advances its agentic finance platformMarks the latest step in the Company's evolution as it continues building out its leadership team to support initiatives serving the Global South NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- SkyAI, Inc. (NASDAQ: "SKYA") ("SkyAI" or the "Company"), a financial technology company building agentic finance for the Global South, today announced the appointment of Arthur Levine as Chief Financial Officer, effective immediately. Mr. Levine will be a key member of the Executive Team as SkyAI builds out its infrastructure to support the next phase o

    5/29/26 8:30:00 AM ET
    $SKYA
    $STSS
    Blank Checks
    Finance
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

    ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    9/20/23 7:22:47 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    SEC Filings

    View All

    Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    6/1/26 7:40:29 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sharps Technology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - SkyAI, Inc. (0001737995) (Filer)

    6/1/26 8:15:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form S-1 filed by Bullfrog AI Holdings Inc.

    S-1 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    5/29/26 4:34:33 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Levine Arthur

    3 - SkyAI, Inc. (0001737995) (Issuer)

    6/3/26 4:30:48 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Financials

    Live finance-specific insights

    View All

    Sharps Technology Adopts Limited Duration Stockholder Rights Plan

    MELVILLE, N.Y., May 14, 2026 /PRNewswire/ -- Sharps Technology, Inc. ("Sharps Technology" or the "Company") (NASDAQ:STSS) today announced that its Board of Directors has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect stockholder interests. The Board adopted the Rights Plan following recent accumulations of the Company's common stock in order to protect the interests of the Company and its stockholders. The Rights Plan is intended to better ensure that all stockholders have the opportunity to realize the value of their investment. Further, it is

    5/14/26 6:07:00 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

    Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it will report its first quarter 2026 operating and financial results via press release to be issued on Friday, May 15. The press release will discuss financial results for the first quarter ended March 31, 2026 and provide operational updates on clinical trials and the development of the Company's AI platforms. About Lantern Pharma Lantern Pharma (NASDAQ:LTRN) is a clinical-stage AI-driven precision oncology company trans

    5/11/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th

    3/30/26 4:05:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care